leuprolide

loo-PROE-lide

Therapeutic Classification: antineoplastics

Pharmacologic Classification: hormones, gonadotropin releasing hormones

High Alert

Advanced prostate cancer.
Central precocious puberty.
Endometriosis (as monotherapy or in combination with norethindrone).
Uterine fibroids (in combination with iron).

Acts as an agonist of gonadotropin releasing hormone (GnRH) receptors.
Initially causes a transient increase in testosterone; however, with continuous administration, testosterone levels are decreased.
Reduces gonadotropins, testosterone, and estradiol.

Therapeutic effects:

Decreased testosterone levels and resultant decrease in spread of prostate cancer.
Reduction of pain/lesions in endometriosis.
Decreased growth of fibroids.
Delayed puberty.

Absorption: Rapidly and almost completely absorbed following SUBQ administration. More slowly absorbed following IM administration of depot form.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-Life: 3 hr.

( effect on hormone concentration)

ROUTE	ONSET‡	PEAK‡	DURATION§
SUBQ	within 1st wk	2–4 wk	4–12 wk
IM	within 1st wk	2–4 wk	4–12 wk
IM-depot	within 1st wk	2–4 wk	4–12 wk

‡Initial transient ↑ in testosterone and estradiol concentrations.

‡Maximum decline in testosterone and estradiol concentrations.

§Restoration of normal pituitary-gonadal function; in amenorrheic patients, normal menses usually returns 60–90 days after treatment is discontinued.

Contraindicated in:

Hypersensitivity to GnRH agonists;
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Hypersensitivity to benzyl alcohol (results in induration and erythema at SUBQ site);
Congenital long QT syndrome, HF, electrolyte abnormalities, or concurrent use of other drugs known to prolong the QT interval;
Seizures, cerebrovascular disorders, CNS tumor, or concurrent use of bupropion or SSRIs;
Rep: Women of reproductive potential;
Pedi: Children <1 yr (safety and effectiveness not established).

CV: angina, arrhythmias, DEEP VEIN THROMBOSIS (DVT), edema, MI. , DepotQT interval prolongation

Derm: Depothair growth, rash, ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS (AGEP), DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), ERYTHEMA MULTIFORME, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN), SUBQdry skin, hair loss, pigmentation, skin cancer, skin lesions

EENT: blurred vision, Depotepistaxis, throat nodules, SUBQhearing disorder

Endo: hot flushes, breast swelling, breast tenderness, hyperglycemia

F and E: hypercalcemia

GI: anorexia, diarrhea, dysphagia, nausea, vomiting, Depotgingivitis, HEPATOTOXICITY, nonalcoholic fatty liver disease, SUBQGI BLEEDING, hepatic impairment, peptic ulcer, rectal polyps

GU: ↓fertility (men), ↓libido, ↓testicular size, dysuria, incontinence, testicular pain, Depotcervix disorder, SUBQbladder spasm, penile swelling, prostate pain, urinary obstruction

Local: burning, itching, swelling at injection site

Metab: Depothyperlipidemia, hyperuricemia

MS: fibromyalgia, ↑bone pain(transient; prostate cancer only), Depot↓bone density, SUBQankylosing spondylitis, joint pain, pelvic fibrosis, temporal bone pain

Neuro: SUBQaggression, anger, anxiety, dizziness, dysgeusia, headache, impatience, intracranial hypertension (children), irritability, lethargy, memory disorder, mood swings, peripheral neuropathy, SEIZURES, STROKE, syncope, Depotdepression, drowsiness, intracranial hypertension (children), personality disorder

Resp: hemoptysis, PULMONARY EMBOLISM (PE), SUBQcough, pleural rub, pulmonary fibrosis, pulmonary infiltrate

Misc: chills, fever, tumor flare, Depotbody odor

Drug-drug:

↑antineoplastic effects with antiandrogens (megestrol, flutamide).
Bupropion or SSRIs may ↑ risk of seizures.
QT interval prolonging drugs may ↑ risk of QT interval prolongation.

Advanced Prostate Cancer

SUBQ (Adults ): Leuprolide acetate: 1 mg/day; Eligard: 7.5 mg once monthly, 22.5 mg every 3 mo, 30 mg every 4 mo, or 45 mg every 6 mo. Camcevi: 42 mg every 6 mo.
IM (Adults ): Lupron Depot: 7.5 mg once monthly or 22.5 mg every 3 mo or 30 mg every 4 mo or 45 mg every 6 mo.

Endometriosis

IM (Adults ): Lupron Depot: 3.75 mg once monthly for up to 6 mo or 11.25 mg every 3 mo for up to 2 doses; if symptoms recur after initial course of therapy, may administer a 2nd course of therapy.

Uterine Fibroids

IM (Adults ): Lupron Depot: 3.75 mg once monthly for up to 3 mo or 11.25 mg single injection.

Central Precocious Puberty

SUBQ (Children ≥2 yr): Leuprolide acetate: 50 mcg/kg/day; may ↑ by 10 mcg/kg/day as required. Fensolvi: 45 mg every 6 mo.
IM (Children ≥1 yr and >37.5 kg): Lupron Depot-Ped (monthly formulation): 15 mg every 4 wk; may ↑ by 3.75 mg every 4 wk as required.
IM (Children ≥1 yr and 26–37.5 kg): Lupron Depot-Ped (monthly formulation): 11.25 mg every 4 wk; may ↑ by 3.75 mg every 4 wk as required.
IM (Children ≥1 yr and ≤25 kg): Lupron Depot-Ped (monthly formulation): 7.5 mg every 4 wk; may ↑ by 3.75 mg every 4 wk as required.
IM (Children ≥1 yr): Lupron Depot-Ped (3-month formulation): 11.25 or 30 mg every 3 mo.
IM (Children ≥1 yr): Lupron Depot-Ped (6-month formulation): 45 mg every 6 mo.

(Generic available)

Emulsion for injection (Camcevi) (prefilled syringe): 42 mg
Lyophilized microspheres for depot injection (Lupron Depot): 3.75 mg; 7.5 mg; 11.25 mg; 22.5 mg; 30 mg; 45 mg
Lyophilized microspheres for depot injection (Lupron Depot-Ped): 7.5 mg; 11.25 mg; 15 mg; 30 mg; 45 mg
Lyophilized powder for injection (Fensolvi): 45 mg/vial
Polymeric matrix injectable formulation for injection (Eligard): 7.5 mg; 22.5 mg; 30 mg; 45 mg
Solution for injection (leuprolide acetate): 1 mg/0.2 mL

Monitor ECG periodically in patients at risk for QT interval prolongation. Assess for palpitations, change in heartbeat, dizziness, shortness of breath, and fainting. Assess for signs of thromboembolic events (DVT, PE, MI, stroke).
Assess skin for AGEP (small red-white or red elevations with pus). Assess for DRESS (rash with fever, lymphadenopathy, hepatitis, hematologic abnormalities). Assess for TEN (red, painful raw skin near eyes, mouth/throat, and gentials/urethra/anus). Assess for SJS (flu-like symptoms, rash with blisters). Assess for erythema multiforme (target or bull’s-eye lesions, red circular patches with concentric rings on hands, feet, face, and mucous membranes).
Monitor for seizure activity. Implement seizure precautions if indicated.
Prostate Cancer: Assess for an ↑ in bone pain, especially during the 1st few weeks of therapy. Monitor patients with vertebral metastases for ↑ back pain and ↓ sensory/motor function.
- Monitor intake and output; assess for bladder distention in patients with urinary tract obstruction during initiation of therapy.
Fibroids: Assess for severity of symptoms (bloating, pelvic pain, pressure, excessive vaginal bleeding) periodically during therapy.
Endometriosis: Assess for endometrial pain prior to and periodically during therapy.
Central Precocious Puberty: Before therapy, confirm diagnosis of central precocious puberty by onset of secondary sex characteristics in girls <8 yr or boys <9 yr. A complete physical and endocrinologic examination, including height, weight, and hand and wrist x-ray; total sex steroid level (estradiol or testosterone); adrenal steroid level; beta human chorionic gonadotropin level; GnRH stimulation test; and computerized tomography of the head must be performed. These parameters are monitored after 1–2 mo and every 3–6 mo during therapy.
- Assess for signs of precocious puberty (menses, breast development, testicular growth) periodically during therapy. Dose is ↑ until no progression of the disease is noted either clinically or by lab test parameters and then usually maintained throughout therapy. Discontinuation of therapy should be considered before age 11 in girls and age 12 in boys.

Lab Test Considerations:

Verify negative pregnancy test before starting therapy.Initially ↑ and then ↓ luteinizing hormone and follicle-stimulating hormone. This leads to castration levels of testosterone in boys 2–4 wk after initial ↑ in concentrations.
- Monitor testosterone, prostatic acid phosphate, and prostate-specific antigen levels to evaluate response to therapy. Transient ↑ in levels may occur during the 1st mo of therapy for prostate cancer.
- Monitor electrolytes before starting and periodically during therapy. May cause ↑ BUN, calcium, uric acid, hypoproteinemia, LDH, alkaline phosphatase, AST, hyperglycemia, hyperlipidemia, hyperphosphatemia, WBC, PT, or aPTT. May ↓ platelets and potassium.
- Monitor blood sugar and A1c periodically during therapy.

SUBQ:

Camcevi: Must be administered by a health care provider. Allow prefilled syringe to stand at room temperature for 30 min before injection. Wear gloves during preparation and administration. Inject into upper or midabdominal area with sufficient soft or loose SUBQ tissue that has not recently been used. Clean the injection site with an alcohol swab. Do NOT inject in areas with brawny or fibrous SUBQ tissue or locations that can be rubbed or compressed (with a belt or clothing waistband). Avoid applying heat directly to the site of injection. Pinch skin and inject at 90° angle; release skin and inject full contents of syringe.
Eligard SUBQ formulation: Bring to room temperature before mixing. Reconstitution: Assemble the Eligard kit and reconstitute solution using syringes provided, as directed by manufacturer. Wearing gloves, mix in syringes as directed by manufacturer; do not shake. Solution must reach room temperature before administration and must be administered within 30 min of mixing or discarded. Solution is light tan to tan in color. Inject into abdomen, upper buttocks, or anywhere that has adequate amounts of SUBQ tissue without excessive pigment, nodules, lesions, or hair. Vary site with each injection. Store in refrigerator; may also be stored at room temperature in original packing for up to 8 wk before mixing.
Fensolvi: Must be administered by a health care provider. Allow to reach room temperature before reconstitution. Reconstitution: Follow manufacturer’s instructions for assembling syringes and mixing. Concentration: 45 mg/0.375 mL. Administer within 30 min or discard. Inject into abdomen or upper buttocks. Avoid areas that have excessive pigment, nodules, lesions, or hair. Pinch skin and inject at 90° angle. Release skin and inject slowly. Rotate injection sites.

Do not confuse Lupron Depot with Lupron Depot-Ped.
- Norethindrone acetate 5 mg daily may be used to prevent bone density loss from leuprolide.
- Correct electrolyte abnormalities before starting therapy.
IM: Use syringe supplied by manufacturer. Rotate sites.
- Leuprolide depot is only for IM injection.
- Lupron Depot formulation and Lupron Depot-Ped must be administered by a health care provider. Reconstitution: To prepare for injection, screw white plunger into end stopper until stopper begins to turn. Hold syringe upright; release diluent by slowly pushing, over 6–8 sec, until the first stopper is at the blue line in the middle of the barrel. Keep syringe upright. Mix microspheres by shaking syringe until power forms a unified suspension. Tap syringe if caking or clumping occurs. Do not combine syringes or partial syringes to arrive at a dose of Lupron Depot-Ped. Suspension will appear milky. Do not use if powder does not go into suspension. Keep syringe upright; remove cap and expel air. Inject at 90° angle in gluteal area, anterior thigh, or deltoid; aspirate and discard if blood in syringe. Suspension settles very quickly; mix and administer immediately. Administer within 2 hr or discard. Rotate injection sites.

Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy.
Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care provider before taking other medications.
Advise patient that medication may cause hot flushes. Notify health care provider if these become bothersome.
Leuprolide depot usually causes a temporary discontinuation of menstruation. Advise patient to notify health care provider if menstruation persists or if intermittent bleeding occurs.
Inform patient of the possibility of the development or worsening of depression and occurrence of memory disorders.
Advise patient of the risk of MI, stroke, and other thromboembolic events. Advise to immediately report signs and symptoms associated with these events to their health care provider for evaluation or seek immediate medical attention.
Inform patient of the risk of seizures. Advise to immediately contact their health care provider if they experience any seizure activity.
Rep: May cause fetal harm. Advise women of reproductive potential to use effective contraception during therapy. Advise patient to notify health care provider if pregnancy is planned or suspected or if breastfeeding. Advise patient that leuprolide may impair fertility.
Prostate Cancer: Instruct patient and family on SUBQ injection technique. Review patient insert provided with leuprolide patient administration kit.
- Instruct patient to take medication exactly as directed. Take missed doses as soon as remembered unless not remembered until next day.
- Inform patient that bone pain may ↑ at initiation of therapy, but will resolve with time. Advise patient to discuss use of analgesics to control pain with health care provider.
- Instruct patient to notify health care provider promptly if difficulty urinating, weakness, or numbness occurs.
Endometriosis: Advise patient to use a form of contraception other than oral contraceptives during therapy. Inform patient that amenorrhea is expected but does not guarantee contraception. Advise patient that breastfeeding should be avoided during therapy.
Central Precocious Puberty: Instruct patient and caregivers on the proper technique for SUBQ injection. Emphasize the importance of administering the medication at the same time each day. Rotate injection sites periodically.
- Inform patient and caregivers that if injections are not given daily, pubertal process may be reactivated.
- Advise patient and caregivers that during the 1st 2 mo of therapy, patient may experience a light menstrual flow or spotting. Health care provider should be notified if this continues beyond 2nd mo.
- Instruct patient and caregivers to notify health care provider immediately if irritation at the injection site or unusual signs or symptoms occur.

Decreased testosterone levels and resultant decrease in spread of prostate cancer.
Reduction of pain/lesions in endometriosis.
Decreased growth of fibroids.
Delayed puberty.

Camcevi, Eligard, Fensolvi, ~~Lupron,~~ Lupron Depot, Lupron Depot-Ped

Zeulide Depot

NDC Code

0074- AbbVie Inc.
- 0074-2108- Lupron Depot-PED
  - 0074-2108-03- 1 KIT in 1 CARTON (0074-2108-03) * 1 mL in 1 SYRINGE * 1 SWAB in 1 PACKET

0074- AbbVie Inc.
- 0074-2282- Lupron Depot-PED
  - 0074-2282-03- 1 KIT in 1 CARTON (0074-2282-03) * 1 mL in 1 SYRINGE * 1 SWAB in 1 PACKET

0074- AbbVie Inc.
- 0074-2440- Lupron Depot-PED
  - 0074-2440-03- 1 KIT in 1 CARTON (0074-2440-03) * 1 mL in 1 SYRINGE * 1 SWAB in 1 PACKET

0074- AbbVie Inc.
- 0074-3346- Lupron Depot
  - 0074-3346-03- 1 KIT in 1 CARTON (0074-3346-03) * 1.5 mL in 1 SYRINGE * 1 SWAB in 1 PACKET

0074- AbbVie Inc.
- 0074-3473- Lupron Depot
  - 0074-3473-03- 1 KIT in 1 CARTON (0074-3473-03) * 1 SWAB in 1 PACKET * 1.5 mL in 1 SYRINGE

0074- AbbVie Inc.
- 0074-3575- Lupron Depot-PED
  - 0074-3575-01- 1 KIT in 1 CARTON (0074-3575-01) * 1.5 mL in 1 SYRINGE (0074-3410-01) * 2 SWAB in 1 PACKET (0074-0010-01)

0074- AbbVie Inc.
- 0074-3641- Lupron Depot
  - 0074-3641-03- 1 KIT in 1 CARTON (0074-3641-03) * 1 mL in 1 SYRINGE * 1 mL in 1 PACKET

0074- AbbVie Inc.
- 0074-3641- Lupron Depot
  - 0074-3641-71- 1 KIT in 1 CARTON (0074-3641-71) * 1 mL in 1 SYRINGE * 1 mL in 1 PACKET

0074- AbbVie Inc.
- 0074-3642- Lupron Depot
  - 0074-3642-03- 1 KIT in 1 CARTON (0074-3642-03) * 1 mL in 1 SYRINGE * 1 SWAB in 1 PACKET

0074- AbbVie Inc.
- 0074-3663- Lupron Depot
  - 0074-3663-03- 1 KIT in 1 CARTON (0074-3663-03) * 1.5 mL in 1 SYRINGE * 1 mL in 1 PACKET

0074- AbbVie Inc.
- 0074-3683- Lupron Depot
  - 0074-3683-03- 1 KIT in 1 CARTON (0074-3683-03) * 1.5 mL in 1 SYRINGE * 1 SWAB in 1 PACKET

0074- AbbVie Inc.
- 0074-3779- Lupron Depot-PED
  - 0074-3779-03- 1 KIT in 1 CARTON (0074-3779-03) * 1.5 mL in 1 SYRINGE * 1 SWAB in 1 PACKET

0074- AbbVie Inc.
- 0074-9694- Lupron Depot-PED
  - 0074-9694-03- 1 KIT in 1 CARTON (0074-9694-03) * 1.5 mL in 1 SYRINGE * 1 SWAB in 1 PACKET

0121- PAI Holdings, LLC dba PAI Pharma
- 0121-2106- leuprolide acetate
  - 0121-2106-02- 1 KIT in 1 CARTON (0121-2106-02) * 1 VIAL, MULTI-DOSE in 1 CARTON (0121-1053-02) / 2.8 mL in 1 VIAL, MULTI-DOSE * 1 mL in 1 PACKET (0121-2105-01)

0781- Sandoz Inc
- 0781-4003- Leuprolide Acetate
  - 0781-4003-32- 1 KIT in 1 CARTON (0781-4003-32) * 1 VIAL, MULTI-DOSE in 1 CARTON (0781-3006-42) / 2.8 mL in 1 VIAL, MULTI-DOSE * 1 mL in 1 PACKET

11532- Takeda Pharmaceutical Company Limited
- 11532-1450-
  - 11532-1450-1- 200 SYRINGE in 1 DRUM (11532-1450-1) / 1 mL in 1 SYRINGE

11532- Takeda Pharmaceutical Company Limited
- 11532-1451-
  - 11532-1451-1- 200 SYRINGE in 1 DRUM (11532-1451-1) / 1 mL in 1 SYRINGE

11532- Takeda Pharmaceutical Company Limited
- 11532-1452-
  - 11532-1452-1- 200 SYRINGE in 1 DRUM (11532-1452-1) / 1 mL in 1 SYRINGE

11532- Takeda Pharmaceutical Company Limited
- 11532-1453-
  11532-1453-1- 200 SYRINGE in 1 DRUM (11532-1453-1) / 1 mL in 1 SYRINGE

11532- Takeda Pharmaceutical Company Limited
- 11532-1454-
  11532-1454-1- 200 SYRINGE in 1 DRUM (11532-1454-1) / 1 mL in 1 SYRINGE

11532- Takeda Pharmaceutical Company LTD
- 11532-1455-
  11532-1455-1- 200 SYRINGE in 1 DRUM (11532-1455-1) / 1.5 mL in 1 SYRINGE

11532- Takeda Pharmaceutical Company Limited
- 11532-1456-
  11532-1456-1- 200 SYRINGE in 1 DRUM (11532-1456-1) / 1.5 mL in 1 SYRINGE

11532- Takeda Pharmaceutical Company Limited
- 11532-1457-
  11532-1457-1- 200 SYRINGE in 1 DRUM (11532-1457-1) / 1.5 mL in 1 SYRINGE

11532- Takeda Pharmaceutical Company LTD
- 11532-3338-
  11532-3338-1- 200 SYRINGE in 1 DRUM (11532-3338-1) / 1.5 mL in 1 SYRINGE

11532- Takeda Pharmaceutical Company Limited
- 11532-3662-
  11532-3662-1- 200 SYRINGE in 1 DRUM (11532-3662-1) / 1.5 mL in 1 SYRINGE

11532- Takeda Pharmaceutical Company LTD
- 11532-3680-
  11532-3680-1- 200 SYRINGE in 1 DRUM (11532-3680-1) / 1.5 mL in 1 SYRINGE

14799- Zhejiang Supor Pharmaceuticals Co., Ltd
- 14799-3005-
  14799-3005-1- 500 g in 1 BAG (14799-3005-1)

14799- Zhejiang Supor Pharmaceuticals Co., Ltd
- 14799-3005-
  14799-3005-2- 100 g in 1 BAG (14799-3005-2)

14799- Zhejiang Supor Pharmaceuticals Co., Ltd
- 14799-3005-
  14799-3005-3- 10 g in 1 BAG (14799-3005-3)

14799- Zhejiang Supor Pharmaceuticals Co., Ltd
- 14799-3005-
  14799-3005-4- 1 g in 1 BAG (14799-3005-4)

35207- BCN PEPTIDES SA
- 35207-0007-
  35207-0007-5- 500 g in 1 BOTTLE (35207-0007-5)

38779- MEDISCA Inc.
- 38779-2629-
  38779-2629-1- 10 g in 1 VIAL (38779-2629-1)

38779- MEDISCA Inc.
- 38779-2629-
  38779-2629-6- 1 g in 1 VIAL (38779-2629-6)

41524- Ambiopharm, Inc.
- 41524-0006-
  41524-0006-1- 1 g in 1 BOTTLE (41524-0006-1)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-10- 1 BOTTLE in 1 BOTTLE (41701-013-10) / 250 g in 1 BOTTLE (41701-013-09)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-12- 1 BOTTLE in 1 BOTTLE (41701-013-12) / 139 g in 1 BOTTLE (41701-013-11)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-20- 1 BOTTLE in 1 BOTTLE (41701-013-20) / 252 g in 1 BOTTLE (41701-013-19)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-24- 1 BOTTLE in 1 BOTTLE (41701-013-24) / 217 g in 1 BOTTLE (41701-013-23)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-26- 1 BOTTLE in 1 BOTTLE (41701-013-26) / 295 g in 1 BOTTLE (41701-013-25)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-30- 1 BOTTLE in 1 BOTTLE (41701-013-30) / 10 g in 1 BOTTLE (41701-013-29)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-38- 1 BOTTLE in 1 BOTTLE (41701-013-38) / 257 g in 1 BOTTLE (41701-013-37)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-40- 1 BOTTLE in 1 BOTTLE (41701-013-40) / 243 g in 1 BOTTLE (41701-013-39)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-42- 1 BOTTLE in 1 BOTTLE (41701-013-42) / 150 g in 1 BOTTLE (41701-013-41)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-44- 1 BOTTLE in 1 BOTTLE (41701-013-44) / 87.5 g in 1 BOTTLE (41701-013-43)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-46- 1 BOTTLE in 1 BOTTLE (41701-013-46) / 139 g in 1 BOTTLE (41701-013-45)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-48- 1 BOTTLE in 1 BOTTLE (41701-013-48) / 286 g in 1 BOTTLE (41701-013-47)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-50- 1 BOTTLE in 1 BOTTLE (41701-013-50) / 222 g in 1 BOTTLE (41701-013-49)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-52- 1 BOTTLE in 1 BOTTLE (41701-013-52) / 100 g in 1 BOTTLE (41701-013-51)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-54- 1 BOTTLE in 1 BOTTLE (41701-013-54) / 111 g in 1 BOTTLE (41701-013-53)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-57- 1 BOTTLE in 1 BOTTLE (41701-013-57) / 156 g in 1 BOTTLE (41701-013-56)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-60- 1 BOTTLE in 1 BOTTLE (41701-013-60) / 86.5 g in 1 BOTTLE (41701-013-59)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-62- 1 BOTTLE in 1 BOTTLE (41701-013-62) / 135 g in 1 BOTTLE (41701-013-61)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-64- 1 BOTTLE in 1 BOTTLE (41701-013-64) / 57 g in 1 BOTTLE (41701-013-63)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-66- 1 BOTTLE in 1 BOTTLE (41701-013-66) / 170 g in 1 BOTTLE (41701-013-65)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-68- 1 BOTTLE in 1 BOTTLE (41701-013-68) / 157 g in 1 BOTTLE (41701-013-67)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-70- 1 BOTTLE in 1 BOTTLE (41701-013-70) / 154 g in 1 BOTTLE (41701-013-69)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-72- 1 BOTTLE in 1 BOTTLE (41701-013-72) / 37 g in 1 BOTTLE (41701-013-71)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-74- 1 BOTTLE in 1 BOTTLE (41701-013-74) / 180 g in 1 BOTTLE (41701-013-73)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-76- 1 BOTTLE in 1 BOTTLE (41701-013-76) / 80 g in 1 BOTTLE (41701-013-75)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-78- 1 BOTTLE in 1 BOTTLE (41701-013-78) / 232 g in 1 BOTTLE (41701-013-77)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-80- 1 BOTTLE in 1 BOTTLE (41701-013-80) / 240 g in 1 BOTTLE (41701-013-79)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-82- 1 BOTTLE in 1 BOTTLE (41701-013-82) / 74 g in 1 BOTTLE (41701-013-81)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-84- 1 BOTTLE in 1 BOTTLE (41701-013-84) / 64 g in 1 BOTTLE (41701-013-83)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-86- 1 BOTTLE in 1 BOTTLE (41701-013-86) / 96 g in 1 BOTTLE (41701-013-85)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-88- 1 BOTTLE in 1 BOTTLE (41701-013-88) / 164 g in 1 BOTTLE (41701-013-87)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-90- 1 BOTTLE in 1 BOTTLE (41701-013-90) / 198 g in 1 BOTTLE (41701-013-89)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-92- 1 BOTTLE in 1 BOTTLE (41701-013-92) / 215 g in 1 BOTTLE (41701-013-91)

41701- Hemmo Pharmaceuticals Pvt. Ltd
- 41701-013-
  41701-013-94- 1 BOTTLE in 1 BOTTLE (41701-013-94) / 221 g in 1 BOTTLE (41701-013-93)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-96- 1 BOTTLE in 1 BOTTLE (41701-013-96) / 119 g in 1 BOTTLE (41701-013-95)

41701- Piramal Pharma Limited
- 41701-013-
  41701-013-98- 1 BOTTLE in 1 BOTTLE (41701-013-98) / 142 g in 1 BOTTLE (41701-013-97)

47335- Sun Pharmaceutical Industries, Inc.
- 47335-936- leuprolide acetate
  47335-936-40- 1 KIT in 1 CARTON (47335-936-40) * 1 VIAL, MULTI-DOSE in 1 CARTON / 2.8 mL in 1 VIAL, MULTI-DOSE * 1 mL in 1 PACKET

51927- Professional Compounding Centers of America
- 51927-0303-
  - 51927-0303-0- 1 g in 1 BOTTLE (51927-0303-0)

55150- Eugia US LLC
- 55150-478- LEUPROLIDE ACETATE
  55150-478-01- 1 KIT in 1 CARTON (55150-478-01) * 1 VIAL, MULTI-DOSE in 1 CARTON (55150-338-01) / 2.8 mL in 1 VIAL, MULTI-DOSE * 1 mL in 1 PACKET (60913-006-01)

59149- PolyPeptide Laboratories, Pvt. Ltd.
- 59149-002-
  - 59149-002-01- 100 g in 1 BOTTLE, GLASS (59149-002-01)

59149- PolyPeptide Laboratories, Pvt. Ltd.
- 59149-002-
  59149-002-02- 1000 g in 1 BOTTLE, GLASS (59149-002-02)

59149- PolyPeptide Laboratories, Pvt. Ltd.
- 59149-002-
  59149-002-03- 500 g in 1 BOTTLE, GLASS (59149-002-03)

59149- PolyPeptide Laboratories, Pvt. Ltd.
- 59149-002-
  59149-002-04- 250 g in 1 BOTTLE, GLASS (59149-002-04)

59149- PolyPeptide Laboratories, Pvt. Ltd.
- 59149-002-
  59149-002-05- 60 g in 1 BOTTLE, GLASS (59149-002-05)

59149- PolyPeptide Laboratories, Pvt. Ltd.
- 59149-002-
  59149-002-06- 125 g in 1 BOTTLE, GLASS (59149-002-06)

59149- PolyPeptide Laboratories, Pvt. Ltd.
- 59149-002-
  59149-002-07- 6 g in 1 BOTTLE, GLASS (59149-002-07)

59149- PolyPeptide Laboratories, Pvt. Ltd.
- 59149-002-
  59149-002-08- 30 g in 1 BOTTLE, GLASS (59149-002-08)

59149- PolyPeptide Laboratories, Pvt. Ltd.
- 59149-002-
  59149-002-09- 125 g in 1 BOTTLE, GLASS (59149-002-09)

59651- Aurobindo Pharma Limited
- 59651-089-
  59651-089-37- 1 kg in 1 BOTTLE, GLASS (59651-089-37)

60870- Aspen Oss B.V.
- 60870-0425-
  60870-0425-0- 1 BOTTLE, PLASTIC in 1 BOX (60870-0425-0) / 300 g in 1 BOTTLE, PLASTIC

60870- Aspen Oss B.V.
- 60870-0471-
  60870-0471-0- 100 g in 1 CONTAINER (60870-0471-0)

60870- Aspen Oss B.V.
- 60870-0472-
  60870-0472-0- 300 g in 1 CONTAINER (60870-0472-0)

62935- TOLMAR Inc.
- 62935-153- Fensolvi
  62935-153-50- 1 KIT in 1 CARTON (62935-153-50) * .375 mL in 1 SYRINGE (62935-154-50) * .375 mL in 1 SYRINGE (62935-155-40)

62935- TOLMAR Inc.
- 62935-163- Fensolvi
  - 62935-163-60- 1 SYRINGE in 1 CARTON (62935-163-60) / .375 mL in 1 SYRINGE

62935- TOLMAR Inc.
- 62935-223- ELIGARD
  - 62935-223-05- 1 KIT in 1 CARTON (62935-223-05) * .375 mL in 1 SYRINGE (62935-221-04) * .375 mL in 1 SYRINGE (62935-224-05)

62935- TOLMAR Inc.
- 62935-227- Eligard
  - 62935-227-10- 1 SYRINGE in 1 CARTON (62935-227-10) / .375 mL in 1 SYRINGE

62935- TOLMAR Inc.
- 62935-303- ELIGARD
  - 62935-303-30- 1 KIT in 1 CARTON (62935-303-30) * .5 mL in 1 SYRINGE (62935-305-29) * .5 mL in 1 SYRINGE (62935-304-30)

62935- TOLMAR Inc.
- 62935-306- Eligard
  - 62935-306-40- 1 SYRINGE in 1 CARTON (62935-306-40) / .5 mL in 1 SYRINGE

62935- TOLMAR Inc.
- 62935-453- ELIGARD
  - 62935-453-45- 1 KIT in 1 CARTON (62935-453-45) * .375 mL in 1 SYRINGE (62935-454-44) * .375 mL in 1 SYRINGE (62935-455-45)

62935- TOLMAR Inc.
- 62935-461- Eligard
  - 62935-461-50- 1 SYRINGE in 1 CARTON (62935-461-50) / .375 mL in 1 SYRINGE

62935- TOLMAR Inc.
- 62935-753- ELIGARD
  - 62935-753-75- 1 KIT in 1 CARTON (62935-753-75) * .25 mL in 1 SYRINGE (62935-754-74) * .25 mL in 1 SYRINGE (62935-755-75)

62935- TOLMAR Inc.
- 62935-756- Eligard
  - 62935-756-80- 1 SYRINGE in 1 CARTON (62935-756-80) / .25 mL in 1 SYRINGE

69097- CIPLA USA INC.
- 69097-909- LEUPROLIDE ACETATE DEPOT
  - 69097-909-50- 1 KIT in 1 CARTON (69097-909-50) * 2 mL in 1 VIAL, SINGLE-DOSE (69097-950-32) * 2 mL in 1 SYRINGE (69097-960-31)

69448- Accord BioPharma, Inc.
- 69448-014- CAMCEVI
  - 69448-014-63- 1 SYRINGE in 1 CARTON (69448-014-63) / .37 g in 1 SYRINGE

69448- Accord BioPharma, Inc.
- 69448-023- CAMCEVI
  - 69448-023-63- 1 SYRINGE in 1 CARTON (69448-023-63) / .37 g in 1 SYRINGE

70121- Amneal Pharmaceuticals LLC
- 70121-2537- leuprolide acetate
  - 70121-2537-6- 1 KIT in 1 CARTON (70121-2537-6) * 1 VIAL, MULTI-DOSE in 1 CARTON (70121-1695-2) / 2.8 mL in 1 VIAL, MULTI-DOSE * 1 mL in 1 PACKET (70121-2538-9)

71052- Darmerica, LLC
- 71052-620-
  - 71052-620-01- 1 g in 1 CONTAINER (71052-620-01)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Code ⬆